HBeAg Seroconversion Rate at 52 and 104 Week
1 clinical trials · Condition
◉ Watch HBeAg Seroconversion Rate at 52 and 104 Week
| Record | Firm | Date |
|---|---|---|
| Efficacy Study of Telbivudine in Chronic Hepatitis B Patients (NCT01958229) | National Taiwan University Hospital | 2009-12-01 |
Track HBeAg Seroconversion Rate at 52 and 104 Week automatically
Every clearance here is in the API, with alerts when new ones post.